- Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation — Recruiting • Phase IV • Cardiology / Cardiovascular • NCT05955365.
- What is being tested: Monotherapy with P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) alone versus dual antiplatelet therapy or anticoagulant-antiplatelet combinations in atrial fibrillation patients undergoing coronary stent implantation, to assess safety and efficacy in reducing both thrombotic and bleeding complications.
- Patient eligibility overview: Patients with diagnosed atrial fibrillation who require percutaneous coronary intervention with Supraflex stent placement, requiring concurrent antithrombotic therapy for both stroke prevention (AF-related) and stent thrombosis prevention (post-PCI).
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined. The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by…
- : * Age ≥18 years * Atrial fibrillation or flutter with an indication for oral anticoagulation using direct-acting oral anticoagulants (DOACs) for ≥12 months * Successful percutaneous coronary intervention in at least 1 lesion within the previous 7 days with no remaining lesions intended for treatment. * Free from major adverse events post qualifying PCI, including new onset chest pain suspected to be of ischemic origin, acute or subacute stent thrombosis, new-onset neurological signs or symptoms. * Written informed consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.